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Abstract 
Background: Eukaryotic RNA polymerase II contains a C‑terminal repeated domain (CTD) consisting of 52 consen‑
sus heptad repeats of Y1S2P3T4S5P6S7 that mediate interactions with many cellular proteins to regulate transcription 
elongation, RNA processing and chromatin structure. A number of CTD‑binding proteins have been identified and 
the crystal structures of several protein‑CTD complexes have demonstrated considerable conformational flexibility of 
the heptad repeats in those interactions. Furthermore, phosphorylation of the CTD at tyrosine, serine and threonine 
residues can regulate the CTD‑protein interactions. Although the interactions of CTD with specific proteins have 
been elucidated at the atomic level, the capacity and specificity of the CTD‑interactome in mammalian cells is not yet 
determined.
Results: A proteomic study was conducted to examine the mammalian CTD‑interactome. We utilized six synthetic 
peptides each consisting of four consensus CTD‑repeats with different combinations of serine and tyrosine phos‑
phorylation as affinity‑probes to pull‑down nuclear proteins from HeLa cells. The pull‑down fractions were then 
analyzed by MUDPIT mass spectrometry, which identified 100 proteins with the majority from the phospho‑CTD 
pull‑downs. Proteins pulled‑down by serine‑phosphorylated CTD‑peptides included those containing the previously 
defined CTD‑interacting domain (CID). Using SILAC mass spectrometry, we showed that the in vivo interaction of RNA 
polymerase II with the mammalian CID‑containing RPRD1B is disrupted by CID mutation. We also showed that the 
CID from four mammalian proteins interacted with pS2‑phosphorylated but not pY1pS2‑doubly phosphorylated CTD‑
peptides. However, we also found proteins that were preferentially pulled‑down by pY1pS2‑ or pY1pS5‑doubly phos‑
phorylated CTD‑peptides. We prepared an antibody against tyrosine phosphorylated CTD and showed that ionizing 
radiation (IR) induced a transient increase in CTD tyrosine phosphorylation by immunoblotting. Combining SILAC and 
IMAC purification of phospho‑peptides, we found that IR regulated the phosphorylation at four CTD tyrosine sites in 
different ways.
Conclusion: Upon phosphorylation, the 52 repeats of the CTD have the capacity to generate a large number of 
binding sites for cellular proteins. This study confirms previous findings that serine phosphorylation stimulates 
whereas tyrosine phosphorylation inhibits the protein‑binding activity of the CTD. However, tyrosine phosphorylation 
of the CTD can also stimulate other CTD‑protein interactions. The CTD‑peptide affinity pull‑down method described 
here can be adopted to survey the mammalian CTD‑interactome in various cell types and under different biological 
conditions.
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Background
The C-terminal repeated domain (CTD) of the larg-
est subunit of RNA polymerase II (RNAPII) consists of 
heptad repeats with the consensus sequence Y1S2P3T-
4S5P6S7, which is modified by phosphorylation during 
each transcription cycle to regulate nascent RNA pro-
cessing and chromatin modifications [1–4]. Previous 
studies have identified many proteins that specifically 
interact with S5-phosphorylated (pS5) or S2-phospho-
rylated (pS2) CTD. For example, the 3’-RNA processing 
factor Pcf11, which contains a CTD-interacting domain 
(CID) [5], preferentially interacts with pS2-CTD [6, 7]; 
whereas the SRI (Set2 Rbp1 interaction) domain of Set2-
histone methyltransferase preferentially interacts with 
pS2pS5-doubly phosphorylated CTD [8]. Furthermore, 
the mammalian capping enzyme Mce1 is activated by its 
interaction with the pS5-CTD [9].
The mammalian RNAPII-CTD is also phosphoryl-
ated on Y1 [10]. Both ABL1 and ABL2 (ARG) tyrosine 
kinases can catalyze the stoichiometric phosphorylation 
of CTD-Y1 on RNAPII in  vitro [10–14]. Recent phos-
pho-proteomics studies have mapped several tyrosine 
phosphorylation sites in the mammalian RNAPII-CTD 
[15, 16], and the yeast RNAPII is also phosphorylated 
on tyrosine by an unknown kinase [17]. An increase in 
the levels of RNAPII tyrosine phosphorylation has been 
observed following DNA damage and correlated with the 
activation of nuclear ABL tyrosine kinase in mammalian 
cell lines and mouse tissues [11, 18]. To determine the 
effect of Y1-phosphorylation (pY1) on the CTD-protein 
binding function, we used CTD-peptides as baits to pull-
down mammalian cellular proteins and identified these 
CTD-interacting proteins by mass spectrometry. We 
used six different CTD peptides, each with four consen-
sus heptad repeats and a unique phosphorylation pattern 
(no phosphorylation, pY1, pS2, pS5, pY1pS2, pY1pS5). We 
found a number of RNA-binding proteins in the pS2- 
and the pS5-peptide pull-down fractions, however, those 
proteins were not pulled-down by the doubly phospho-
rylated pY1pS2-CTD or the pY1pS5-CTD peptides. The 
negative effect of pY1 on the interaction of pS2-CTD with 
the CTD-interaction domain (CID) was confirmative of 
a previous report [17]. However, our study also identi-
fied proteins that were preferentially pulled-down by 
the pY1pS2- or the pY1pS5-CTD peptide, suggesting that 
tyrosine phosphorylation can either inhibit or stimulate 
the protein binding activities of the CTD.
Methods
Reagents
Antibodies for Abl 8E9 (BD), H5, and H14 (Covance), 
c-Myc 9E10, N20, (Santa Cruz), GST (BD), B10 (Milli-
pore), PY20 (Sigma), were used. The biotin-CTD peptides 
were synthesized by AnaSpec (San Jose, CA). Anti-RPB1 
8WG16 monoclonal antibodies were a generous gift from 
Dr. Richard Burgess, University of Wisconsin-Madison. 
Polyclonal pTyr1-CTD, pTyr1pS2, pTyr1pS5 antibodies 
were generated by Pacific Immunology (Ramona, CA) 
by injecting 2 rabbits each with either CTSPSpYSPTS 
peptide, CTSPSpYpSPTS peptide, and CSPTSPpSpYSPT 
peptide, conjugated at the N-terminus to keyhole lim-
pet hemagglutinin and affinity-purified by binding to the 
phosphor-peptide-coupled Sepharose beads. Oligonu-
cleotide primers were synthesized by IDT (San Diego, 
CA). The reactivity of the antibodies was by determined 
by ELISA against biotin-labeled CTD peptides.
Plasmids
3XMyc-human SCAF4 CTD interacting domain was 
generated by ligating PCR products of SCAF4 into KpnI/
XhoI digested pcDNA3.0. Three rounds of PCR using 
were used. The first round used forward primer: 5Kpn-
IMYC15CID (5′-GAC CTA GGT GGG GAA CAG 
AAA CTG ATT TCG GAA GAA GAT CTC ATG GAC 
GCC GTC-3′) and reverse primer XhoI15CID (5′-CCG 
CTC GAG TTA CGC TGC CAT GTC-3′). The sec-
ond round used was forward primer: 5KpnI2ndMYC: 
(5′-GAT CTG GGA GGC GAG CAG AAG CTA ATA 
TCC GAG GAA GAC CTA GGT GGG-3′) and reverse 
primer: XhoI15CID (5′-CCG CTC GAG TTA CGC 
TGC CAT GTC-3′). The third round used forward 
primer: 5KpnI3rdMYC: (5′-GGG GTA CCA TGG AAC 
AAA AAC TCA TCT CAG AAG AGG ATC TGG GAG 
GC-3′) and reverse primer: XhoI15CID (5′-CCG CTC 
GAG TTA CGC TGC CAT GTC-3′). 3XMyc-human 
full length Mutant RPRD1B was generated by ligating 
344 bp DNA fragment-containing mutations synthesized 
by (GeneScript, N57S, D58S, Q61K, N62R) into KpnI/
EcoRI digested RPRD1B pcDNA5.0/FRT. Mutations 
were generated based on the generous amino acid anal-
ysis and modeling of Pcf11 CID to RPRD1B CID by Dr. 
Dong Wang, University of California, San Diego. 6XMyc-
p72 was used unmodified as previously published in 
[19]. The AblPPn plasmid was generated by two rounds 
of ligation: in the first ligation, SbfI/SalI digested frag-
ment from CMV-Abl-PP [20] was ligated to PCR prod-
uct of SalI/μNES/XbaI fragment from Abl NES mutant 
plasmid [21] to generate a SbfI/XbaI fragment containing 
NLS and μNES. In the second round, the SbfI/XbaI frag-
ment was further ligated into SbfI/XbaI digested CMV-
Abl-PP-Nuc. The YF-CTD mutant plasmid used in our 
studies was pAT7Rpb1(FSPTSPS)18 +Cterm Amr, which 
expresses a cDNA of the human Pol II large subunit with 
a truncated CTD containing 18 peptide repeats that have 
the tyrosine residue mutated to phenylalanine and a com-
plete CTD C-terminus. This expressed cDNA has an 
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amino-terminal B10 epitope tag and a carboxy-terminal 
6XHis tag and was a gift from Dr. David Bentley, Univer-
sity of Colorado—Denver.
CTD‑peptide affinity chromatography
HeLa nuclear extracts were prepared as previously 
described [22], with the following modifications: the 
nuclear pellet was sonicated in lysis buffer and spun for 
30  min at maximum speed in a table top centrifuge. The 
supernatant was collected and contained both nucleoplasm 
and chromatin bound proteins. Lysis buffer consisted 
of the following: 10  mM HEPES, pH 7.9, 200  mM NaCl, 
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.5 % NP40, 
0.125 % Sodium deoxycholate, 0.05 % SDS, 10 % glycerol. 
Before use, 10 mM Na2VO4, 10 mM β-Glycerophosphate, 
1 mM NaF, 1 mM PMSF, and 1X protease cocktail inhibi-
tor (Roche) were added. The nuclear extract was incu-
bated with 4 µg of CTD antibody 8WG16 overnight at 4º 
C to immunoprecipitate RNAPII using protein A/G beads 
(Pierce). Prior to immunoprecipitation, the NaCl concen-
tration was adjusted to 400 mM for 30 min. The superna-
tant, i.e., nuclear extract immunodepleted of RNAPII, was 
adjusted to 150 mM NaCl. 100 pmols of each of the six dif-
ferent CTD peptides (four consensus repeats with differing 
phosphorylation’s) were attached to streptavidin-magnetic 
beads per manufacturer instructions (Roche) and incu-
bated with 5 mg of immunodepleted nuclear extract for 6 h 
at 4 °C. Beads were washed three times with binding buffer 
(150 mM NaCl), eluted with SDS-PAGE sample buffer, and 
fractions were silver stained after running on 4–20 % gel. 
The eluted fractions were analyzed by mass spectrometry.
Multidimensional protein identification technology 
(MUDPIT) mass spectrometry
Proteins were reduced and alkylated using 1  mM Tris 
(2-carboxyethyl) phosphine (Fisher, AC36383) at 94  °C 
for 5  min and 2.5  mM iodoacetamide (Fisher, AC12227) 
at 37  °C in dark for 30  min, respectively. Proteins were 
digested with 1 μg trypsin (Roche, 03 708 969 001) over-
night. Supernatant was collected and centrifuged through a 
0.22 μM filter (Fisher# 07-200-386). An Agilent 1100 HPLC 
system (Agilent Technologies, Santa Clara, CA) delivered a 
flow rate of 500 nL per minute to a 3-phase capillary chro-
matography column through a splitter. Using a custom 
pressure cell, 5  µm Zorbax SB-C18 (Agilent) was packed 
into fused silica capillary tubing (200 µm ID, 360 µm OD, 
20 cm long) to form the first reverse phase column (RP1). 
A 5 cm long strong cation exchange (SCX) column packed 
with 5  µm PolySulfoethyl (PolyLC, Inc.) was connected 
to RP1 using a zero dead volume 1  µm filter (Upchurch, 
M548) attached to the exit of the RP1 column. A fused sil-
ica capillary (100 µm ID, 360 µm OD, 20 cm long) packed 
with 5 µm Zorbax SB-C18 (Agilent) was connected to SCX 
as the analytical column (the second reverse phase col-
umn). The electro-spray tip of the fused silica tubing was 
pulled to a sharp tip with the inner diameter smaller than 
1 µm using a laser puller (Sutter P-2000). The peptide mix-
tures were loaded onto the RP1 using the custom pressure 
cell. Columns were not re-used. The peptide mixtures were 
loaded onto the RP1 column using the same in-house pres-
sure cell. To avoid sample carry-over and keep good repro-
ducibility, a new set of three columns with the same length 
was used for each sample. Peptides were first eluted from 
RP1 column to SCX column using a 0–80  % acetonitrile 
gradient for 150 min. The peptides were fractionated by the 
SCX column using a series of 7 step salt gradients (0, 20, 40, 
60, 80, 100 mM, and 1 M ammonium acetate for 20 min), 
followed by high-resolution reverse phase separation using 
an acetonitrile gradient of 0–80 % for 120 min. The mass 
spectrometer was operated in positive ion mode with a 
source temperature of 150 °C and a spray voltage of 1500 V. 
Data-dependent analysis and gas phase separation were 
employed. The full MS scan range of 300–2000 m/z was 
divided into 3 smaller scan ranges (300–800, 800–1100, 
1100–2000  Da) to improve the dynamic range. Each MS 
scan was followed by 4 MS/MS scans of the most intense 
ions from the parent MS scan. A dynamic exclusion of 
1 min was used to improve the duty cycle of MS/MS scans. 
Raw data were extracted and searched using Spectrum Mill 
(Agilent, version A.03.02). MS/MS spectra with a sequence 
tag length of 1 or less were considered as poor spectra and 
discarded. The rest of the MS/MS spectra were searched 
against the IPI (International Protein Index) database lim-
ited to human taxonomy (v3.31, 67,533 protein sequences). 
The enzyme parameter was limited to full tryptic pep-
tides with a maximum mis-cleavage of 1. All other search 
parameters were set to SpectrumMill’s default settings 
(carbamidomethylation of cysteines, ±2.5 Da for precursor 
ions, ±0.7 Da for fragment ions, and a minimum matched 
peak intensity of 50 %). Search results for individual spec-
tra were automatically validated using the filtering criteria 
listed in the following Table.
Filtering criteria for  autovalidation of  database search 
results
Mode Protein score 1+ peptide 2+ peptide 3+ peptide
Protein details >20 >9 >9 >11
Peptide NA >13 >13 >15
A concatenated forward-reverse protein database was 
constructed to calculate the in  situ false discovery rate 
(FDR). The tryptic peptides in the reverse database were 
compared to the forward database, and were shuffled if 
they matched to any tryptic peptides from the forward 
database. The total number of protein sequences in the 
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combined database is 135,069. Proteins that share com-
mon peptides were grouped to address the database 
redundancy issue. The proteins within the same group 
shared the same set or subset of unique peptides. Only 
proteins with 2 or more unique peptides were validated. 
There are 100 proteins observed in the pull-down sam-
ples containing CTD peptides (non-modified CTD, pY1, 
pS2, pS5, pY1pS2, and pY1pS5) but not in the beads only 
control samples. Functional Annotation of these 100 pro-
teins was completed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) [23, 24]. 
There were no proteins from the reverse database passed 
the filters mentioned above, which implies the FDR of 
our protein list is less than 1 %.
Surface plasmon resonance
Sensograms were recorded on a Biacore T200 instru-
ment using streptavidin (SA) chips. All experiments were 
conducted at 25  °C and approximately 1000 response 
units of biotinylated CTD peptides 2.6 nM were immo-
bilized on the chip in a high salt buffer (500 mM NaCl, 
10  mM Tris, pH 7.5, 0.5  mM EDTA). Sensograms were 
run using flow cell 1 (FC 1) as an unmodified reference. 
Data was collected for FC’s 2, 3 and 4, which contained 
differentially phosphorylated CTD peptides. FC2 con-
tained unphosphorylated CTD peptide, FC3 contained a 
CTD peptide only phosphorylated on the serine residue, 
and FC4 contained a CTD peptide that was phosphoryl-
ated on both a serine and tyrosine residue. In all cases 
1.2 nM of CID protein was flowed over the chip at 20 μl/
min with a 3 min contact time and a 3 min dissociation 
phase. The running buffer used for the binding experi-
ments was 10  mM Tris, pH 7.5, 150  mM NaCl, 3  mM 
DTT, and 0.2  mM EDTA. Regeneration was achieved 
using an 8-min pulse of high salt buffer. Each of the four 
GST-CID fusion proteins was expressed in BL21 E.coli 
from pDEST™24-CID and purified using glutathione 
Sepharose (GE Healthcare, Piscataway, NJ) according to 
manufacturer’s instructions.
Co‑immunoprecipitation of recombinant GST‑CTD 
with Myc‑SCAF4‑CID
Human embryonic kidney (HEK) 293T cells were cul-
tured in DMEM supplemented with 10  % Fetal Bovine 
Serum (Hyclone) and 100  µg/ml each of penicillin and 
streptomycin. 293T cells grown in 10 cm plates to 80 % 
confluence were transfected with the indicated plasmid 
using Lipofectamine (InVitrogen) or GeneTran (Biomiga). 
Cells were harvested in cold PBS, lysed in NETN buffer 
(20 mM Tris pH 8.0, 100 mM NaCl, 0.5 mM EDTA, 0.5 % 
Nonident P-40) on ice for 20 min, sonicated and treated 
with RNase and DNase for 1  h. For co-immunoprecipi-
tation experiments, 250-500 µg of total protein was used 
for each immunoprecipitation reaction, either with anti-
Myc (9E10)-conjugated agarose beads or mouse IgG-cou-
pled A/G Sepharose beads for 1 h at 4 °C.
Preparation of partially purified RNA polymerase II 
from HeLa cell nuclear extract
RNA polymerase II was obtained from HeLa cells treated 
with 8  Gy IR. Following IR treatment HeLa cells were 
washed once in ice cold 1X PBS and harvested by centrifug-
ing at 1500g. The cell pellet was incubated on ice for 10 min 
in buffer containing 10 mM HEPES, pH 7.9, 100 mM NaCl, 
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 1.0 % Sapo-
nin, and 10 % glycerol. Before use, 10 mM Na2VO4, 10 mM 
β-Glycerophosphate, 1 mM NaF, 1 mM PMSF, and 1X pro-
tease cocktail inhibitor (Roche) were added. After incu-
bation cells were pelleted by centrifugation at 1000g and 
resuspended in phosphate buffer (PB) and layered onto a 
30 % sucrose cushion and centrifuged at 1500g for 10 min. 
The pellet (nuclei) was resuspended in 10 mM HEPES, pH 
7.9, 150 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM 
DTT, 1 % TritonX100, 10 % glycerol, layered on top of 30 % 
sucrose cushion, and centrifuged at 1500g for 10 min. The 
pellet was washed 3X times with PB and the crude chro-
matin pellet was extracted using increasing amounts of 
ammonium sulfate (NH4)2SO4. The supernatant from the 
0.5 M fraction contained enriched RNA polymerase II and 
was used for phosphopeptide mapping.
Phosphopeptide purification and mapping using 
immobilized metal affinity chromatography (IMAC)
IMAC was prepared as previously described in [25]. Ni 
was strip from the resin by 5 mM EDTA, pH8.0, 100 mM 
NaCl was used to while rotating at room temperature for 
1 h in a 50 ml Falcon tube. The stripped resin is pelleted 
by centrifugation at 1500g and washed twice by 50  ml 
water followed by 50 ml of 0.6 % acetic acid, then, 50 ml 
of 100 mM FeCl3 in 0.3 % acetic acid was used to coor-
dinate iron to NTA resin. Following overnight incuba-
tion the resin is washed three times. The first wash was 
with 50  ml of 0.6  % acetic acid followed by two washes 
with 50 ml each of 0.1 % acetic acid. After the last wash 
the volume of the resin is estimated and resuspended 
in 0.1  % acetic acid as 50  % (vol/vol) slurry and stored 
at 4  °C. All common chemicals used for IMAC resin 
preparation where purchased from (SIGMA-Aldrich). 
SDS was added to the partially purified RNA polymer-
ase II to a final concentration of 1  %. The sample was 
then reduce and alkylated by with 5 mM DTT for 5 min 
at 50  °C and 30 mM iodoacetamide for 45 min at room 
temperature in the dark. Proteins were precipitated 
by adding 3 volumes of 50  % (vol/vol) ethanol/acetone 
for 1 h at 4  °C. The protein pellet was resuspended in a 
buffer composed of 100 mM Tris (pH8.0), 8 M urea. The 
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protein concentration was measured by Bradford assay 
and 1XTBS was used to dilute the urea concentration to 
2 M final. 10 mg of the sample was digested using 0.1 mg 
of trypsin overnight at 37 °C. Following overnight digest 
the sample was acidified with TFA to a final concentra-
tion of 0.2  % and centrifuged at 4000g for 15  min. The 
soluble peptides were loaded into a 500  mg Sep-Pak18 
column and washed twice with 3  ml of 1  % acetic acid, 
then eluted with a buffer composed of 80 % acetonitrile 
and 0.1 % acetic acid and dried by speed vac. The dried 
peptides were resuspended in 100  μl of 1  % acetic acid 
and loaded to IMAC column containing 70 μl of beads. 
The IMAC column was washed 2X twice with buffer con-
taining 25 % acetonitrile, 100 mM NaCl, and 0.1 % acetic 
acid, followed by 1X wash with 1 % acetic acid, and 1X 
wash with water. The bound peptides were finally eluted 
with 210  μl of 6  % ammonium and dried by speed vac. 
Phosphopeptides were resuspended in 80  % acetonitrile 
and fractionated using a 2 mm Amide-80 column. Frac-
tionated samples were resuspended in 5 μl 1 % TFA, and 
a 70 min linear gradient from 10 to 40 % ACN and 0.1 % 
formic acid was used to run the samples into LTQ Orbit-
rap XL similarly to previously described in [25].
MS data analysis using SEQUEST
The tandem mass spectra were searched on Sorcerer-
sequest system (SageN, San Jose, CA SEQUEST) using 
a human semi-tryptic IPI database version 3.80 (down-
load from http://www.ebi.ac.uk/IPI). And quantified 
using XPRESS software from TPP v4.3 rev 1 (Institute 
for Systems Biology). The search parameters used were: a 
monoisotopic masses, 50 ppm for the parental mass tol-
erance, maximum of three modifications per peptide, and 
a 79.966331 amu variable modification for phosphoryla-
tion of serine, threonine, and tyrosine.
SILAC labeling for identification of CID‑dependent 
interactions with RPRD1B
RPRD1B 293 Flp In cells were grown in conditions used 
in [26]. Essentially cells were grown in either heavy or 
light complete DMEM media with 10  % dialyze FBS. 
Before cells reached 80 % confluence TET induction was 
initiated for 36  h. After induction of 3XMYC-RPRD1B 
WT or 3XMYC-RPRD1B MT immunoprecipitation was 
performed using total cell lysate. Immunoprecipitated 
RPRD1B was combined reduced, alkylated, and digested 
by 1 μg of trypsin. Samples were then desalted by 50 mg 
Sep-Pak18 column and dried by speed Vac. Dried sam-
ples were run into a 1  mm amide 80 column, and ana-
lyzed by MS as previously described in [25]. The median 
from the proteins identified with more than three unique 
peptides was calculated, and proteins with 1.0 cutoff for 
heavy to light SILAC ratio were determined.
SILAC labeling for identification of CTD phosphorylation 
sites affected by ionizing radiation
Three independent SILAC labeling experiments were 
performed to determine the effect of ionizing radia-
tion (IR) on CTD phosphorylation in HeLa cells. In 
each experiment, the cells labeled with the heavy amino 
acids were treated with 8  Gy IR and collected at 2  h 
after radiation exposure. The cells labeled with the light 
amino acids were (1) un-irradiated, (2) irradiated with 
8  Gy IR and collected 30  min after radiation exposure, 
or (3) irradiated with 8 Gy IR and collected 60 min after 
radiation exposure. The lysates from each pair of heavy 
and light amino acids labeled cells were mixed and RNA 
polymerase II partially purified as described above. The 
partially purified RNA polymerase II was then subjected 
to trypsin digestion and phospho-peptide analysis as 
described above. The phosphorylation sites in the phos-
pho-containing CTD peptides were quantitated using 
XPRESS software from TPP v4.3 rev 1 (Institute for Sys-
tems Biology) described above.
Results
Phospho‑CTD‑peptide pull‑down of cellular proteins
A previous study employed biotinylated CTD-peptides 
with different combinations of serine phosphorylation 
to investigate the interaction of cellular proteins with the 
CTD repeats [27]. We adopted this approach to identify 
CTD-interacting proteins from HeLa nuclear extracts. 
We synthesized six CTD-peptides (Fig. 1a), each contain-
ing four Y1S2P3T4S5P6S7 consensus repeats with a biotin 
at the N-terminus, and each with a different phosphoryla-
tion status: (1) unphosphorylated, (2) phosphorylated at 
the four tyrosines (pY1) at the first position, (3) phospho-
rylated at the four serines at the second position (pS2), 
(4) phosphorylated at the four serines at the fifth position 
(pS5) and (5, 6) combinations thereof (pY1pS2 and pY1pS5). 
HeLa nuclear extracts immunodepleted of the endogenous 
RNAPII were reacted with each of the six different CTD 
peptides and bound proteins were identified using multi-
dimensional protein identification technology (MUDPIT). 
Silver staining displayed the complexity of each of the 
streptavidin pull-down fractions (Fig. 1b) and showed that 
the pS2 and pS5 CTD-peptides pulled-down more pro-
teins than the unphosphorylated or the pY1 CTD-peptides 
(Fig. 1b, compare lanes 5 and 6 to lane 3, 4). Furthermore, 
the pattern of protein bands pulled-down by the doubly 
phosphorylated pY1pS2 or the pY1pS5 CTD-peptides was 
dissimilar to that pulled-down by the singularly phospho-
rylated CTD-peptides (Fig.  1b, compare lanes 7–5, and 
8–6). The six pull-down fractions were analyzed by mass 
spectrometry in two independent experiments. The first 
by analyses of silvered stained gel bands and the second by 
MUDPIT analyses of the entire pull-down fraction. A total 
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of 100 proteins were identified from the MUDPIT experi-
ment as summarized in Table  1. Of them, several were 
also identified by the analysis of gel bands (see proteins 
marked with ** in Table 1). Some of the proteins in Table 1 
are known to directly interact with serine-phosphorylated 
CTD, e.g., those containing the CTD-interacting domain 
(CID) (see below). Other proteins pulled-down by the 
CTD-peptides may represent direct, indirect or non-spe-
cific interactions. It cannot be ruled out that these inter-
actions are RNA or DNA dependent, because the nuclear 
extracts were not treated with nucleases to remove RNA 
or DNA. A likely example of a non-specific interaction 
would be GAPDH, an abundant cytosolic protein detected 
in the pull-down fractions of 4 CTD-peptides (Table  1). 
a b
c d
Fig. 1 Proteomic analysis of proteins pulled‑down by phosphorylated CTD peptides. a Summary of experimental strategy. Six CTD‑peptides with 
phosphorylation sites marked in red and biotinylation at the N‑terminus marked as a circle were synthesized and used as affinity probes to pull‑
down proteins from HeLa nuclear extracts. b A representative silver stained gel of proteins pulled‑down by the six CTD‑peptides. c, d Graphical 
representations of bioinformatics analysis of CTD‑interacting proteins separated by GO terms in biological process (c) or molecular function (d). The 
CTD‑interaction proteins are listed in Table 1
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Table 1 Proteins Identified by the MUDPIT analyses of CTD-peptide pull-down fractions






Score Beads CTD tyr1 ser2 ser5 ser2tyr1 ser5tyr1
ESYT2 IPI00409635 38 25 423.67 0 0 0 0 0 46 104
ESYT1 IPI00022143 39 31 497.94 0 0 0 0 0 43 96
PLD1 IPI00218797 29 25 370.49 0 0 0 0 0 17 52
HSP90B1 IPI00027230 24 17 254.42 0 2 0 0 8 5 50
HSPE1 IPI00220362 67 10 134.68 0 3 1 0 7 3 41
CANX IPI00020984 23 14 196.91 0 0 0 3 0 0 38
PDIA6 IPI00299571 24 9 151.87 0 0 0 0 4 4 34
TRAP1 IPI00030275 14 8 134.8 0 0 0 0 5 0 29
PDIA3 IPI00025252 30 12 176.8 0 0 0 0 4 2 23
P4HB IPI00010796 24 11 157.3 0 1 0 0 2 1 22
ATP1A1 IPI00006482 13 11 161.54 0 0 0 0 1 0 19
RPL4 IPI00003918 16 6 96.02 0 1 0 7 0 0 19
GAPDH IPI00219018 24 7 103.11 0 2 0 0 3 6 17
TUFM IPI00027107 20 7 109.33 0 0 0 0 0 1 16
RPN1 IPI00025874 19 10 117.2 0 0 0 2 0 0 15
LRRC59 IPI00396321 28 7 101.92 0 0 0 0 0 2 15
SFPQ IPI00010740 11 6 83.98 0 2 0 0 4 1 15
DDX21** IPI00015953 17 13 174.19 0 0 0 5 0 0 14
LMNA IPI00021405 16 10 138.09 0 0 0 0 1 0 14
ATP5B IPI00303476 16 6 97.21 0 0 0 0 0 3 13
KHSRP IPI00479786 18 9 129.15 0 0 0 0 2 0 12
TUBB IPI00011654 10 3 51.99 0 0 0 0 0 1 12
CALR IPI00020599 31 9 123.08 0 0 0 0 2 1 11
ALDOA IPI00796333 20 5 85.11 0 0 0 0 2 3 11
RAB7A IPI00016342 26 5 80.8 0 0 0 0 3 0 11
ATP5A1 IPI00440493 14 7 96.43 0 0 0 0 2 2 10
RCN1 IPI00015842 28 7 90.96 0 0 0 0 0 2 10
TKT IPI00788802 12 6 84.06 0 1 0 0 0 0 10
RPN2 IPI00028635 10 4 61.66 0 1 0 0 0 0 10
RPL7A IPI00479315 23 7 97.03 0 0 0 3 0 0 9
HNRPU IPI00644079 10 7 95.98 0 0 0 2 0 1 9
SERBP1 IPI00410693 15 5 79.22 0 0 0 0 1 1 9
SLC25A5 IPI00007188 17 5 68.2 0 0 0 0 0 1 9
RTN4 IPI00021766 2 3 50.99 0 0 0 1 1 0 9
HNRPC** IPI00477313 26 8 111.38 0 0 0 5 0 0 8
VIM IPI00418471 21 9 110.44 0 0 0 0 0 2 8
NONO IPI00304596 16 8 98.5 0 0 0 0 5 0 8
ANXA2 IPI00418169 24 6 93.12 0 0 0 0 0 1 8
MATR3 IPI00789551 12 7 92.94 0 0 0 2 0 0 8
DDX5** IPI00017617 9 6 79.42 0 0 0 3 0 0 8
PPIB IPI00646304 25 6 69.98 0 0 0 0 2 0 8
RPL18 IPI00215719 21 4 54.14 0 0 0 4 0 0 8
RPL6 IPI00790342 26 7 105.24 0 0 0 7 0 0 7
CROP IPI00107745 11 3 52.2 0 0 0 0 0 4 7
RAB1A IPI00005719 18 3 45.79 0 0 0 0 2 1 7
PRKCSH IPI00026154 8 3 53.39 0 0 0 0 1 0 6
RPRD2 IPI00384541 34 38 543.2 0 0 0 63 0 20 5
PHF3 IPI00170770 17 28 411.08 0 0 0 13 0 83 5
HNRNPUL2 IPI00456887 7 5 67.71 0 0 0 0 0 3 5
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Table 1 continued






Score Beads CTD tyr1 ser2 ser5 ser2tyr1 ser5tyr1
RPL7 IPI00472171 13 4 56.17 0 0 0 3 0 0 5
RPL29 IPI00796934 15 3 44.49 0 0 0 1 0 1 5
KIAA1429 IPI00036742 10 17 253.56 0 0 0 14 0 13 4
ZC3H13 IPI00329547 7 12 154.87 0 0 0 7 0 5 4
WTAP IPI00220302 25 8 120 0 0 0 4 0 3 4
RBMX** IPI00304692 15 6 75.41 0 0 0 6 0 0 4
HNRPD IPI00028888 8 3 42.87 0 0 0 0 1 0 4
TMPO IPI00216230 6 3 40.25 0 0 0 0 1 0 4
SSBP1 IPI00029744 22 2 32.28 0 0 0 0 2 0 4
SFRS3 IPI00010204 14 2 28.23 0 0 0 0 0 0 4
RBM15** IPI00102752 18 16 217.62 0 0 0 21 0 9 3
NPM1 IPI00549248 17 4 60.16 0 1 0 1 0 1 3
RPL8 IPI00797230 14 4 52.41 0 2 0 4 0 0 3
RPL23A IPI00789159 16 3 46.69 0 0 0 3 0 0 3
RPL15 IPI00375511 16 4 46.24 0 0 0 10 0 0 3
RPL28 IPI00182533 18 3 37.93 0 0 0 3 0 0 3
LOC654188 IPI00419585 16 3 34.68 0 0 0 0 1 0 3
RPL35 IPI00412607 15 2 31.35 0 0 0 4 0 0 3
RPS14 IPI00026271 15 2 30.42 0 1 0 0 0 0 3
hCG_2040224 IPI00412855 13 2 27.87 0 0 0 2 0 0 3
DST IPI00074148 0 2 25.88 0 2 1 0 1 1 3
RPRD1B IPI00009659 24 8 121.65 0 0 0 40 0 6 2
RPS9 IPI00221088 20 4 51.03 0 0 0 2 0 0 2
HNRNPH1 IPI00479191 12 4 50.57 0 0 0 0 2 0 2
RPL26 IPI00433834 11 3 35.94 0 0 0 3 0 0 2
SUMO2 IPI00299149 23 2 31.08 0 0 0 0 1 0 2
HNRPM** IPI00171903 5 4 49.84 0 0 0 3 0 0 1
LOC641293 IPI00845507 18 3 38.98 0 0 0 3 0 0 1
RPL31 IPI00848331 25 3 35.4 0 0 0 2 0 0 1
PRSS1 IPI00011694 9 3 34.11 0 10 39 0 5 13 1
SF3A1 IPI00017451 4 2 31.33 0 1 0 0 0 0 1
RPL10 IPI00646899 8 2 30.62 0 0 0 7 0 0 1
AOC3 IPI00004457 1 2 26.37 0 0 0 0 3 1 1
LOC730004 IPI00787417 23 2 24.8 0 1 0 0 0 0 1
TMPRSS13 IPI00000848 3 2 24.18 0 10 36 0 4 14 1
LACTB IPI00749059 24 10 145.3 0 0 0 0 0 15 0
SCAF8 IPI00744707 7 9 107.99 0 0 0 17 0 0 0
SCAF4 IPI00181702 6 7 82.65 0 0 0 12 0 1 0
RNGTT IPI00000104 7 4 58.94 0 0 0 0 11 0 0
GC IPI00555812 9 3 43.86 0 3 0 0 0 0 0
DSP IPI00013933 1 3 42.82 0 3 0 0 0 0 0
FKBP15 IPI00401282 2 3 36.89 0 0 0 0 0 5 0
CBLL1 IPI00290429 5 2 34.71 0 0 0 4 0 0 0
HNRNPUL1** IPI00013070 3 3 32.92 0 0 0 8 0 0 0
MGAM IPI00220143 1 2 27.01 0 0 0 0 2 0 0
STOML2 IPI00334190 8 2 23.18 0 0 0 0 0 2 0
KIAA1881 IPI00787298 1 2 22.61 0 0 0 0 2 0 0
PRPF6 IPI00305068 1 2 22.54 0 2 0 0 0 0 0
DIDO1 IPI00619921 1 2 22.43 0 0 0 0 0 2 0
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However, many other proteins were pulled-down by only 
one of the six CTD peptides tested (Table 1).
Bioinformatics analysis using Annotation, Visualization 
and Integrated Discovery (DAVID) of the proteins listed in 
Table 1 found that the majority of them fall into the Bio-
logical Process of RNA splicing and metabolism (Fig. 1c). 
DAVID also found the Biological Process of translation and 
the structural constituent of ribosome to be represented 
(Fig.  1c, d). Given the abundance of ribosomal constitu-
ent and the cytoplasmic location of translation, the ribo-
somal proteins in the pull-down fractions are most likely 
to be non-specific. On the other hands, Table 1 contains 
several RNA-binding proteins that are related to known 
components of the human spliceosomal complexes [28], 
and those interactions are likely to be relevant because the 
CTD is known to regulate RNA splicing.
CID binds pS2‑CTD but not pY1pS2‑CTD
The CTD-interacting domain (CID) was previously 
identified by a yeast two-hybrid screen for CTD-bind-
ing proteins [29]. Subsequent studies have determined 
that the CID domain of the transcription termination 
factor Pcf11 interact with phosphorylated serine resi-
dues of CTD (pS2-CTD) [30], but not with CTD that is 
doubly phosphorylated on tyrosine and serine (pY1pS2-
CTD) [17]. In Fig.  2a, the complex of Pcf11-CID with 
pS2-CTD is overlaid with the CID of SCAF8 (Fig. 2a) [6, 
7, 30, 31]. Although Pcf11 was not among the proteins 
pulled-down by the pS2-CTD peptide, four other CID-
proteins, namely SCAF8, SCAF4, RPRD1B, and RPRD2 
were identified in the pS2-CTD but not in the pY1pS2-
CTD pull-down fractions (Table 1; Fig. 2b). To validate 
the differential interaction between the CID and the dif-
ferent phosphorylated CTD peptides, we expressed and 
purified the CIDs from SCAF4, SCAF8, RPRD1B, and 
RPRD2 as GST-fusion proteins from bacteria (Fig.  2c). 
Direct interaction between each CID and the biotin-
CTD, biotin-pS2-CTD and biotin-pY1pS2-CTD pep-
tides were analyzed by surface plasmon resonance using 
streptavidin-coated Biacore chips (Fig.  2d) [27, 32]. 
Consistent with the MUPIT results (Table 1) as well as 
previously published reports [17, 30], we detected bind-
ing of all four CIDs to the pS2-CTD peptide but not to 
the unphosphorylated CTD peptide or the doubly phos-
phorylated pY1pS2-CTD peptide (Fig. 2d).
We then examined the interaction of the SCAF4-CID 
with a recombinant GST-CTD protein and with the 
CTD peptides by immunoprecipitation and pull-down 
assays (Fig. 3). As shown in Fig. 3b, HEK293T cells were 
transfected with GST (lane 1), GST-CTD (lane 2), Myc-
SCAF4-CID (lane 3), Myc-p72b (lane 4) or combinations 
(lanes 5–8). Total cell lysates were probed with antibod-
ies for GST or Myc to determine the levels of the trans-
fected proteins. The cell lysates were each reacted with 
anti-Myc (9E10) or IgG conjugated agarose beads and the 
precipitated samples were then immunoblotted with anti-
GST (Fig.  1c). The results showed that Myc-SCAF4-CID 
but not Myc-p72b (encoded by DDX17, which is another 
RNA binding protein involved in RNA processing) inter-
acted with GST-CTD in co-transfected cells (Fig. 3c, lane 
7). In Fig. 3d, total lysate from HEK293T cells transfected 
with the Myc-SCAF4-CID expression plasmid was reacted 
with pS2-CTD and pY1pS2-CTD peptides over a range of 
concentrations. The pull-down fractions were then probed 
with anti-Myc. Densitometry quantification of the immu-
noblots detecting Myc showed a concentration-dependent 
interaction of Myc-SCAF4-CID with the pS2-CTD pep-
tide but not the pY1pS2-CTD peptide (Fig. 3d). Together, 
results shown in Table 1, Figs. 2 and 3 establish that CTD 
tyrosine-1 phosphorylation disrupts the CID interaction 
with pS2-CTD. These results are consistent with a previous 
report that Pcf11 interaction with the CTD is disrupted by 
CTD tyrosine phosphorylation [17].
CID‑dependent interaction of RPRD1B with RNA 
polymerase II
To demonstrate that a mammalian CID containing pro-
tein associates with endogenous RNA polymerase II, we 
generated mutations in the CID domain of the human 
RPRD1B protein. The mutant RPRD1B contains four 
amino acid substitutions: N57S, D58S, Q61K, N62R, in 
its CID domain (Fig. 4a) [7]. To determine whether these 
Table 1 continued






Score Beads CTD tyr1 ser2 ser5 ser2tyr1 ser5tyr1
DSG1 IPI00025753 2 2 22.18 0 2 0 0 0 0 0
DSC1 IPI00216099 3 2 20.02 0 2 0 0 0 0 0
Lists the proteins that were identified from peptide pull-down using differentially phosphorylated CTD peptides. The official gene symbol and accession number are 
listed in the first two columns. Percent coverage column shows the percentage of the protein’s sequence represented by the peptides identified in the MS/MS analysis. 
Unique peptides column shows total number of peptides that were identified. Score: score from Spectrum Mill. The other columns show the total number of peptides 
identified in each of the indicated pull-down fractions with beads alone (no peptide), and each of the six CTD peptides illustrated in Fig. 1a. Proteins marked by ** 
were those identified in two independent experiments by (a) MS/MS identification of gel bands in the pull-down fractions and (b) MUDPIT identification of the entire 
pull-down fractions. The four CID-containing proteins are highlighted in italics. Note that the MUDPIT experiment identified more proteins, which are listed here
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Fig. 2 CID binding to pS2‑CTD but not pY1pS2‑CTD. a Left crystal structure of the Pcf11 CID domain in complex with a pS2‑CTD peptide (PDB ID: 
1SZA); Right superimposition of the CID domain of Pcf11 and SCAF8 (PDB ID: 3D9I). b Amino acid alignment of the CID domains in the indicated 
proteins. c GST‑CID fusions from each of the indicated CID‑containing proteins were purified from bacterial lysates using glutathione affinity 
chromatography. d Binding of the indicated GST‑CID to the indicated CTD‑peptides was determined by surface plasmon resonance using BIA 
evalution version 3.1. Unphosphorylated CTD peptide is represented by blue line. pS2‑CTD peptide is represented by red line. pY1pS2‑CTD peptide is 
represented by green line
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Fig. 3 Co‑immunoprecipitation of Myc‑SCAF4‑CID with recombinant CTD. a A diagram of mammalian expression constructs expressing GST‑CTD 
and Myc‑fusion proteins. b Total lysates from HEK293T cells transfected with GST (lane 1), GST‑CTD (lane 2), Myc‑SCAF4‑CID (lane 3), Myc‑p72b (lane 
4) or the indicated combinations (lanes 5–8) were immunoblotted with anti‑GST or anti‑Myc to detect the expression of GST‑CTD or the Myc‑
fusions. c Cell lysates as in (a) were immunoprecipitated with anti‑Myc (9E10) and probed with anti‑GST. Total lysates from co‑transfected samples 
(lanes 5–8) were also immunoprecipitated with mouse IgG (lanes 9–12) and probed with anti‑GST. d Binding of Myc‑SCAF4‑CID to biotin‑pS2‑CTD 
but not biotin‑pY1pS2‑CTD peptides. The indicated amount of each biotinylated CTD‑peptide was reacted with 50 µg of total lysates from HEK293T 
cells transfected with the Myc‑SCAF4‑CID expression plasmid and then pulled down by streptavidin beads. Values shown in the upper panel are 
mean and standard deviation of densitometry quantification of anti‑Myc immunoblotting for the Myc‑SCAF4‑CID in the pull‑down fraction from 
three independent experiments. Representative blots of total lysate (input) and the pull‑down fractions are shown in the lower panel





Fig. 4 Interaction of full‑length Myc‑RPRD1B but not CID‑mutant Myc‑RPRD1B with RNAPII and the CTD. a Diagram of full‑length wild type (WT) 
RPRD1B and mutant (MT) RPRD1B containing the following point mutations N57S, D58S, Q61K, N62R in the CID. AblPPn is a constitutively activated 
Abl kinase in which two proline residues (PP) in the SH2‑kinase linker are mutated to glutamic acids to disrupt auto‑inhibition, and a leucine residue 
to inactivate the nuclear export signal (n). b WT but not MT RPRD1B interacts with endogenous RNAPII. Total lysates from HEK293T cells transfected 
vector (lane 1), WT Myc‑RPRD1B (lane 2), MT Myc‑RPRD1B (lane 3), were immunoblotted with the anti‑Myc and anti‑8WG16 to detect RPRD1B and 
RNAPII (left panels). These cell lysates were also immunoprecipitated with anti‑Myc (9E10) to detect the co‑immunoprecipitation of endogenous 
RNA polymerase II (N20) and pS2‑CTD (right panels). c WT but not MT RPRD1B interacts with recombinant CTD. Total lysates from HEK293T cells 
transfected with GST (lane 1), GST‑CTD (lane 2), or combinations with Myc‑RPRD1B (lanes 3–8) and probed with anti‑GST or anti‑Myc (left panels, 
input). These lysates were also immunoprecipitated with anti‑Myc (9E10) and probed with anti‑ pSer2‑CTD or anti‑GST. d C‑transfection with AblPPn 
inhibited RPRD1B interaction with CTD. Total lysates (input) from HEK293T cells transfected with GST (lane 1), CTD (lane 2), WT RPRD1B (lane 3), MT 
RPRD1B (lane 4), or combinations (lanes 5–8) including those with AblPPn (lanes 9, 10) were probed with anti‑Myc (upper panel). These ten lysates 
(1–10) were immunoprecipitated with anti‑Myc (MYC IP) and the immunoprecipitates probed with anti‑GST (lanes 11–20, lower panel). Note that 
GST‑CTD associated with WT but not MT RPRD1B, and that AblPPn disrupted WT RPRD1B interaction with GST‑CTD (compare lane 17–19). e Dia‑
gram of SILAC mass spectrometry strategy used to identify proteins that associated with WT but not MT RPRD1B. Heavy and light isotope labeling 
was conducted after tetracyclin‑induced expression of the WT and MT RPRD1B in HEK293T cells. See Tables 3 and 4 for summaries of SILAC results
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CID mutations disrupt RPRD1B interaction with endog-
enous RNA polymerase II, HEK293T cells were trans-
fected with the wild type or mutant Myc-tagged RPRD1B 
expression plasmids and the amount of RNAPII or pS2-
CTD in the anti-Myc (9E10) immunoprecipitates was 
detected by immunoblotting (Fig.  4b). Immunoblotting 
of total lysates (Fig. 4b, lanes 1–3) with anti-Myc showed 
that the wild type (WT) and the CID-mutant (MT) 
RPRD1B were both expressed in the transfected cells. 
Following immunoprecipitation with anti-Myc (9E10)-
conjugated agarose beads, RNAPII and pS2-CTD were co-
immunoprecipitated with the WT Myc-RPRD1B, but not 
the CID-mutated (MT) Myc-RPRD1B (Fig.  4b). We also 
examined the interaction of the WT and the MT RPRD1B 
with recombinant GST-CTD. As shown in Fig.  4c, 
HEK293T cells were transfected with GST (lane 1), GST-
CTD (lane 2), WT RPRD1B (lane 3), MT RPRD1B (lane 
4) and in combinations (lanes 5–8) the expressed pro-
teins were detected via immunoblotting with anti-Myc 
and anti-GST in total lysates (input) (Fig.  4c). Following 
immunoprecipitation using anti-Myc (9E10) conjugated-
agarose beads, the precipitated samples were immunob-
lotted with anti-GST and anti-pS2 (Fig.  4c, lanes 9–16). 
Again, WT RPRD1B associated with pS2-CTD (lane 15) 
but MT RPRD1B did not associate with pS2-CTD.
To test if tyrosine phosphorylation of the CTD could 
disrupt the interaction between CID and CTD, HEK293T 
cells were co-transfected with GST (lane 1), GST-CTD 
(lane 2), Myc-RPRD1B WT (lane 3), Myc-RPRD1B MT 
(lane 4) or combinations with an constitutively activated 
ABL kinase (AblPPn) (lanes 5–10), and total cell lysates 
(input) were analyzed via immunoblottings to detect the 
transfected proteins (Fig. 4d). The AblPPn contains three 
amino acid substitution mutations to disrupt auto-inhibi-
tion and to inhibit nuclear export (Fig. 4a) [21, 33]. These 
lysates were also subjected to immunoprecipitation using 
anti-Myc (9E10) conjugated-agarose beads and the pre-
cipitates probed with anti-GST (Fig.  4d, lanes 11–20). 
It was observed that the association between RPRD1B 
and CTD was disrupted by the co-expression of AblPPn 
(comparing lane 17–19 in Fig. 4d), correlating with tyros-
ine phosphorylation of the endogenous RNAPII and 
GST-CTD (see Fig. 5 below).
We next used SILAC proteomics to identify cellular 
proteins that differentially associated with the WT vs. the 
MT RPRD1B in HEK293T cells (Fig. 4e; Table 2). We con-
structed HEK293 cells to stably express either the WT or 
the MT RPRD1B from a tetracycline-inducible promoter. 
Following tetracycline induction, we labeled the WT 
RPRD1B expressing cells with heavy amino acids, and 
the MT cells with light amino acids, subjected the labeled 
lysates to immunoprecipitation with anti-Myc conju-
gated-beads, and analyzed the resulting immunoprecipi-
tates by tandem mass spectrometry. As summarized in 
Table 2, 79 proteins were identified to have a median WT/
MT ratio of greater than 1.0. It is important to note that 
the bait protein (RPRD1B) had a median WT/MT ratio 
of 1.16. The mass spectrometry analysis achieved an over 
77 % coverage of RPRD1B in 22 distinct peptides. Bioin-
formatics analysis of WT-RPRD1B-associated proteins 
found that the top two biological processes represented 
were RNA processing (p value 1.1E−29) and mRNA 
metabolic process (p value 9.7E−27) (Table  3). The top 
two cellular components represented are ribonucleopro-
tein complex (p value 2.4E−20) and nucleoplasm (p value 
2.0E−17) (Table  3). The top molecular function repre-
sented was RNA binding (p value 7.5E−24) (Table  3). 
As summarized in Table 4, six RNA polymerase II subu-
nits were found to associate with wild type RPRD1B and 
each with a WT/MT ratio of greater than 2.5, which is 
(See figure on next page.) 
Fig. 5 Reactivity of anti‑pY1‑CTD with CTD‑peptides and endogenous RNAPII. a Representative images of ELISA results. Each column is coated with 
a different CTD peptide as indicated on the bottom of the columns. Each row is reacted with a different antibody as indicated to the left of the rows. 
4G10 is a mouse monoclonal antibody that reacts with phosphor‑tyrosine; 8WG16 is a mouse monoclonal antibody that reacts with un‑phospho‑
rylated CTD; α‑pS5 is rabbit polyclonal antibody that reacts with pS5 in CTD; α‑pS2 is a rabbit polyclonal antibody that reacts with pS2 in CTD; α‑pY1 
is a rabbit polyclonal antibody raised against a pY1pS5‑CTD peptide. b Quantification of ELISA results. Numbers shown are mean ± SD (n = 3). 
c Phosphotyrosine (pTyr) competed with the binding of α‑pY1 to pY1‑containing CTD peptides. d α‑pY1‑CTD reacts with endogenous RNAPII. 
HEK293T cells transfected with vector or AblPPn were immunoprecipitated with 8WG16 or IgG and then probed with N20 or anti‑pY1. Transfection 
with AblPPn increased the pY1‑reactivity in whole cell lysate (input) and in 8WG16‑precipitated RNAPII (upper panels). RNAPII CTD contains 52 CTD‑
repeats and not all 52 repeats are stoichiometrically phosphorylated in vivo, 8WG16 can react with RNAPII that contains some unphosphorylated 
CTD repeats and some pY1‑CTD repeats. In reciprocal immunoprecipitation (IP), whole cell lysates were reacted with anti‑pY1 and then immunob‑
lotted with anti‑pS5‑CTD or 8WG16. Note that anti‑pY1 immunoprecipitated RNAPII that reacted with anti‑pS5‑CTD or 8WG16. IIo, RNAPII containing 
hyper‑phosphorylated CTD; IIA, RNAPII with hypo‑phosphorylated CTD. e The previously reported 3D12 antibody [17] does not react with pY1‑CTD. 
Increasing amounts of total lysates from HEK293T cells transfected with vector or AblPPn were immunoblotted with the indicated antibodies. Note 
that AblPPn did not alter the levels of pS2 or pS5 reactive RNAPII but increased the levels of pY1 reactive RNAPII. The pY1‑reactivity was competed 
with phosphotyrosine (pTyr). Note that 3D13 reacts with the IIA form of RNAPII. Reactivity with 3D12 was not affected by the expression of AblPPn. 
Phosphotyrosine does not inhibit the 3D12 reactivity with RNAPIIA. f Anti‑pY1‑CTD does not react with YF‑CTD mutant. HEK293T cells were trans‑
fected with combinations of AblPPn, GST, GST‑CTD or a RNAPII with a truncated CTD in which all of the Y1 is mutated to F (phenylalanine). Whole 
cell lysates were immunoblotted with the indicated antibodies. Note that pS5 reacted with the endogenous RNAPII, GST‑CTD and the YF‑RNAPII. 
The authenticity of the YF‑RNAPII was established by its reactivity with B10 antibody [34]. The YF‑RNAPII did not react with anti‑pY1‑CTD
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significantly above the ratio of the bait RPRD1B protein 
(Table  4). Over 20 unique peptides were identified as 
Rpb1, which encodes the largest subunit containing the 
CTD, with a median WT/MT ratio of 9.0. These results 
confirmed that the CID domain of RPRD1B is important 
for its association with the endogenous RNAPII enzyme 
complex in mammalian cells. Future investigation of the 
interactions between RPRD1B and the proteins identified 
in this study (Table 2) will provide clues to the biological 
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Characterization of antibodies for tyrosine‑phosphorylated 
CTD
Antibodies for serine-2 and serine-5 phosphorylated CTD 
have been available for many years; however, antibodies 
for tyrosine-1-phosphorylated CTD were only recently 
Table 2 Summary of SILAC MS analysis of proteins associ-
ated with wild-type (WT) vs. CID-mutated (MT) RPRD1B





Amino acid  
coverage 
(%)
POLR2A 9.090909091 20 18.1
POLR2B 7.142857143 17 19.7
RECQL5 4 5 6.2
POLR2C 2.941176471 9 45.8
POLR2D 2.941176471 4 33.8
POLR2E 2.739726027 4 26.2
POLR2I 2.666666667 4 62.4
RPLP2 2.127659574 7 51.3
SKIV2L2 1.5625 3 2.9
NOLC1 1.418439716 4 7.3
EIF2C3 1.408450704 3 17.4
SUPT4H1 1.298701299 3 27.4
SF3A3 1.282051282 3 6.2
DDX3X|DDX3Y 1.265822785 11 32
CSTF3 1.25 5 11.9
TOP3B 1.25 3 9.2
NHP2 1.242236025 6 28.1
DDX5 1.234567901 14 13.3
PARP1 1.234567901 6 9.1
RBM42 1.234567901 4 7.5
RUVBL2 1.234567901 6 12.2
SFRS15 1.234567901 3 2.4
TNRC6B 1.234567901 9 12.6
TFG 1.204819277 5 21
DPF2 1.19760479 8 30.7
PRPF19 1.19047619 5 19.2
CSTF1 1.183431953 6 22.3
DDX5|DDX17 1.183431953 6 30.5
MRPL15 1.176470588 3 18.6
RUVBL1 1.176470588 8 26.8
SNRPD2 1.176470588 10 68.6
SMARCC1 1.169590643 8 20.5
TNRC6C 1.169590643 4 6.2
GTF2I 1.162790698 7 11.9
HMGN2 1.162790698 5 36.7
NUP153 1.162790698 11 10.8
NUP214 1.162790698 9 6.6
RPRD1B 1.156069364 22 77
DDX42 1.149425287 3 3.6
SEC23B 1.149425287 6 15.5
SEC31A 1.149425287 17 18.9
ZNF638 1.149425287 3 5
NUP98 1.142857143 8 7.8
SNRNP70 1.142857143 12 35










Amino acid  
coverage 
(%)
DDX3X 1.123595506 3 32
FAU 1.123595506 3 32
SNRPG 1.123595506 3 48.7
RPS7 1.117318436 10 42.6
CDKN2AIP 1.111111111 15 36
CNOT1 1.111111111 3 2.1
EIF2C1 1.111111111 9 21
HNRNPH3 1.111111111 4 15
TP53 1.104972376 6 22.9
PRKRA 1.098901099 3 14.1
PCBP1 1.092896175 4 25
PCF11 1.092896175 6 4.4
FAM98B|FAM98A 1.086956522 3 57.9
FMR1 1.086956522 3 5.5
LRRC59 1.086956522 3 20.5
SF3B3 1.086956522 9 11
DDX17 1.081081081 22 42.4
WDR33 1.081081081 4 5.4
CPSF1 1.075268817 15 14.3
HIST1H1A 1.075268817 3 50.2
SEC24C 1.075268817 16 18.2
CPSF2 1.069518717 10 17.9
HMGA1 1.069518717 4 36.5
DHX9|NPL 1.063829787 3 19.1
EIF2C2 1.063829787 11 30.4
HNRNPD 1.063829787 15 48.4
RBM17 1.063829787 15 20.4
SNRPA 1.063829787 9 36.1
CHERP 1.052631579 8 9.9
DAP3 1.052631579 3 5.8
RPS17 1.052631579 4 34.8
RPS2 1.052631579 3 14.2
SNRPD1 1.052631579 3 58.8
Lists proteins that were identified to preferentially associate with wild type (WT) 
RPRD1B, but not CID-mutated (MT) RPRD1B utilizing a SILAC mass spectrometry 
strategy where heavy and light isotope labeling was conducted after 
tetracycline-induced expression of the WT and MT RPRD1B in HEK293T cells. 
The official gene symbols of the identified proteins are listed in the first column. 
The column labeled Median WT/MT is the median ratio between a heavy and 
light matching peptide identified for that protein. Unique peptides column 
shows the total number of peptides that were identified and exists in only one 
protein regardless of peptide length. Amino acid coverage column shows the 
percentage of the protein’s sequence represented by the peptides identified in 
the MS analysis
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reported [17]. To develop anti-pY1-CTD antibodies, we 
immunized rabbits with three different tyrosine phospho-
rylated CTD peptides: pY1-consensus peptide, pY1pS2-
concensus peptide, and pY1pS5-consensus peptide and 
purified phospho-specific antibodies by peptide-affinity 
chromatography. We found that the pY1-consensus pep-
tide generated anti-pY1 antibody of low affinity. Immu-
nization with the pY1pS2-peptide generated antibodies 
that reacted with pY1, pS2, pY1pS2, pS5, and pY1pS5-CTD 
peptides. However, immunization with pY1pS5-CTD 
Table 3 Functional Annotation of RPRD1B Interacting Proteins
Summarizes DAVID analysis of RPRD1B interacting proteins listed in Table 1. Gene Ontology terms of biological process (GOTERM_BP), cellular component (GOTERM_
CC), and molecular function (GOTERM_MF) are shown. The column designated Count shows the number of genes in the GO term. Percent column shows the number 
of genes out of the total for each GO term. P-Value, Benjamini, and FDR, are statistical measures to determine confidence of gene enrichment in each GO term
Category Term Count % P value Benjamini FDR
GOTERM_BP_FAT RNA processing 36 42.9 1.10E−29 4.90E−27 1.60E−26
GOTERM_BP_FAT mRNA metabolic process 30 35.7 9.70E−27 2.10E−24 1.40E−23
GOTERM_BP_FAT mRNA processing 28 33.3 1.20E−25 1.80E−23 1.70E−22
GOTERM_BP_FAT RNA splicing 27 32.1 1.30E−25 1.40E−23 1.80E−22
GOTERM_BP_FAT RNA splicing, via transesterification reactions with bulged adenosine as nucleo‑
phile
22 26.2 2.10E−24 1.80E−22 2.90E−21
GOTERM_BP_FAT nuclear mRNA splicing, via spliceosome 22 26.2 2.10E−24 1.80E−22 2.90E−21
GOTERM_BP_FAT RNA splicing, via transesterification reactions 22 26.2 2.10E−24 1.80E−22 2.90E−21
GOTERM_BP_FAT macromolecular complex assembly 20 23.8 1.40E−09 1.00E−07 2.00E−06
GOTERM_BP_FAT macromolecular complex subunit organization 20 23.8 4.10E−09 2.60E−07 5.80E−06
GOTERM_BP_FAT RNA elongation from RNA polymerase II promoter 7 8.3 2.10E−07 1.10E−05 2.90E−04
GOTERM_BP_FAT mRNA cleavage 5 6 2.50E−07 1.20E−05 3.50E−04
GOTERM_BP_FAT RNA elongation 7 8.3 3.00E−07 1.30E−05 4.20E−04
GOTERM_BP_FAT gene silencing by RNA 6 7.1 8.40E−07 3.30E−05 1.20E−03
GOTERM_BP_FAT chromosome organization 14 16.7 1.70E−06 6.00E−05 2.30E−03
GOTERM_BP_FAT transcription initiation from RNA polymerase II promoter 7 8.3 1.70E−06 5.60E−05 2.40E−03
GOTERM_BP_FAT chromatin organization 12 14.3 5.30E−06 1.60E−04 7.40E−03
GOTERM_BP_FAT chromatin assembly or disassembly 8 9.5 5.30E−06 1.50E−04 7.50E−03
GOTERM_BP_FAT transcription initiation 7 8.3 5.40E−06 1.50E−04 7.70E−03
GOTERM_CC_FAT ribonucleoprotein complex 28 33.3 2.40E−20 3.40E−18 2.90E−17
GOTERM_CC_FAT nucleoplasm 31 36.9 2.00E−17 1.40E−15 2.30E−14
GOTERM_CC_FAT nuclear lumen 37 44 6.90E−17 5.20E−15 1.30E−13
GOTERM_CC_FAT intracellular organelle lumen 39 46.4 9.60E−16 3.50E−14 1.20E−12
GOTERM_CC_FAT organelle lumen 39 46.4 2.00E−15 5.60E−14 2.40E−12
GOTERM_CC_FAT membrane‑enclosed lumen 39 46.4 4.00E−15 9.40E−14 4.70E−12
GOTERM_CC_FAT nucleoplasm part 19 22.6 5.00E−10 1.00E−08 5.90E−07
GOTERM_CC_FAT spliceosome 11 13.1 2.00E−09 3.50E−08 2.30E−06
GOTERM_CC_FAT DNA‑directed RNA polymerase II, core complex 6 7.1 7.60E−09 1.20E−07 9.00E−06
GOTERM_CC_FAT nuclear DNA‑directed RNA polymerase complex 6 7.1 1.90E−07 2.70E−06 2.30E−04
GOTERM_CC_FAT DNA‑directed RNA polymerase complex 6 7.1 1.90E−07 2.70E−06 2.30E−04
GOTERM_CC_FAT RNA polymerase complex 6 7.1 2.40E−07 3.10E−06 2.80E−04
GOTERM_CC_FAT non‑membrane‑bounded organelle 33 39.3 9.60E−07 1.10E−05 1.10E−03
GOTERM_CC_FAT intracellular non‑membrane‑bounded organelle 33 39.3 9.60E−07 1.10E−05 1.10E−03
GOTERM_CC_FAT DNA‑directed RNA polymerase II, holoenzyme 7 8.3 4.70E−06 5.10E−05 5.50E−03
GOTERM_CC_FAT chromosome 13 15.5 5.60E−06 5.60E−05 6.60E−03
GOTERM_MF_FAT RNA binding 35 41.7 7.50E−24 9.00E−22 8.60E−21
GOTERM_MF_FAT purine NTP‑dependent helicase activity 9 10.7 7.10E−08 4.20E−06 8.10E−05
GOTERM_MF_FAT ATP‑dependent helicase activity 9 10.7 7.10E−08 4.20E−06 8.10E−05
GOTERM_MF_FAT helicase activity 10 11.9 8.20E−08 3.30E−06 9.40E−05
GOTERM_MF_FAT DNA‑directed RNA polymerase activity 6 7.1 4.00E−06 1.20E−04 4.60E−03
GOTERM_MF_FAT RNA polymerase activity 6 7.1 4.00E−06 1.20E−04 4.60E−03
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peptide generated antibody that reacted with pY1-CTD, 
pY1pS2-CTD and pY1pS5-CTD but not the serine-only 
phosphorylated peptides (Fig.  5a, b). This reactivity was 
competed by phosphotyrosine (Fig.  5c), demonstrating 
that the antibody recognizes the pY1-epitope. The pY1-
antibody also reacted with endogenous RNA polymerase 
II in cells transfected with AblPPn (Fig.  5d). We found 
a significant increase in the reactivity of endogenous 
RNAPII with our anti-pY1 antibody in cells transfected 
with AblPPn (Fig. 5e). The ectopic expression of AblPPn 
did not alter the reactivity of RNAPII with the pS5- or the 
pS2-CTD antibodies (Fig.  5e). We purchased the previ-
ously reported pY1-CTD antibody 3D12 [17]. Despite the 
report that this antibody reacts with Abl-phosphorylated 
CTD, we could not repeat that result. As shown in Fig. 5e, 
the 3D12 antibody reacted with the unphosphoryl-
ated RNAPII and its reactivity was not stimulated by the 
ectopic expression of AblPPn. To further demonstrate the 
specificity of our pY1-CTD antibody, we tested its reactiv-
ity against the YF-CTD mutant of RNAPII. As shown in 
(Fig. 5f ), the pY1-CTD antibody did not react with the YF-
CTD mutant.
Ionizing radiation alters CTD tyrosine phosphorylation
Previous studies have shown that the nuclear Abl is acti-
vated by DNA damage to phosphorylate RNAPII-CTD 
on tyrosine [11, 18]. We therefore examined IR induced 
tyrosine phosphorylation of RNA polymerase II CTD 
using phospho-proteomics combined with SILAC. A 
multistep purification strategy was established to gener-
ate an enriched partially purified fraction of RNA poly-
merase II that preserved its native phosphorylation state 
(Fig.  6a). The fractions were characterized using immu-
noblotting to detect total RNA polymerase II and phos-
phorylation of serine 2 or serine 5 on CTD (Fig.  6b). 
SILAC tandem mass spectrometry was then used to com-
pare the CTD phospho-peptides at 2  h after exposure 
to 8  Gy ionizing radiation (IR) relative to un-irradiated, 
30 min irradiated or 60 min irradiated cells (Fig. 6c). As 
summarized in Table 5, our analysis identified a subset of 
the previously identified CTD phosphorylation sites, i.e., 
Y-1874, Y-1881, Y-1909 and Y-1916 that are in the vicin-
ity of the few Lys residues in the CTD. Among this subset 
of trypsin-released peptides, our SILAC analysis showed 
that ionizing radiation affected CTD tyrosine phospho-
rylation in several ways.
A phospho-peptide containing pY-1874 and pY-1881 
but no pS or pT showed similar levels (ratio of 0.91) 
between non-irradiated and irradiated cells at 2  h, but 
reduced ratio (0.5) when the comparison was made 
between cells irradiated for 30  min or 2  h, suggest-
ing that IR caused a transient reduction in pY-1874 and 
pY-1881 at 30  min with a return to un-irradiated level 
by 2  h (Table  5). The ratio of 0.75 between 60  min and 
2 h irradiated samples was consistent with this transient 
reduction and recovery of phosphorylation at these two 
tyrosine sites. A phospho-peptide containing pY-1909 
and also pS-1917 and pS-1920 showed reduced lev-
els in un-irradiated and 30  min-irradiated relative to 
2  h-irradiated samples (Table  5). This result suggests 
that IR caused an increase in the abundance of this pY-
containing CTD peptide between 30  min to 2  h of IR. 
A pY-1909, pS-1915 and pS-1920 peptide also showed 
increased abundance with time from 30 to 60 min rela-
tive to 2 h after irradiation (Table 5). Interestingly, a pep-
tide with pY-1909 and pS-1920 was found at higher levels 
in un-irradiated cells when compared to 2  h-irradiated 
cells (Table 5). There are two possible interpretations of 
these results. First, the decrease in pY-1909/pS-1920 pep-
tide may be coupled to the increase in pY-1909/pS-1917/
pS-1920 peptide and thus suggesting that IR induced 
the phosphorylation of pS-1917. Second, the decrease 
in pY-1909/pS1920 peptide is not related to the increase 
in pY1909/pS-1917/pS-1920 peptide in that these two 
Table 4 RNA polymerase subunits identified in RPRD1B interactome
Lists RNA polymerase subunits identified to associate with wild type (WT) RPRD1B, but not the CID-mutated (MT) RPRD1B, from the SILAC mass spectrometry 
experiment where heavy and light isotope labeling was conducted after tetracycline-induced expression of the WT and MT RPRD1B in HEK293T cells. The official gene 
symbols of the identified proteins are listed in the first column. The column labeled Median WT/MT is the median ratio between a heavy and light matching peptide. 
Unique peptides column shows the total number of peptides that were identified and exist in only one protein regardless of peptide length. Amino acid coverage 
column shows the percentage of the protein’s sequence represented by the peptides identified in the MS analysis
Gene symbol Median (WT/MT) Unique peptide Amino acid coverage (%) Protein
POLR2A 9.09 20 18.1 POLR2A DNA‑directed RNA polymerase II subunit RPB1
POLR2B 7.14 17 19.7 POLR2B DNA‑directed RNA polymerase II subunit RPB2
POLR2C 2.94 9 45.8 POLR2C DNA‑directed RNA polymerase II subunit RPB3
POLR2D 2.94 4 33.8 POLR2D DNA‑directed RNA polymerase II subunit RPB4
POLR2E 2.74 4 26.2 POLR2E DNA‑directed RNA polymerased I, II, and III subunit 
RPABC1
POLR2I 2.67 4 62.4 DNA‑directed RNA polymerase II subunit RPB9
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phosphorylation configurations occurred on differ-
ent RNAPII molecules and that IR regulated their levels 
independently, dependent on the sub-genomic locations 
of these different RNAPII. With peptides containing the 
pY-1916 site, our SILAC analyses consistently showed a 
reduction in abundance at 2-h after IR (Table 5). It thus 
appears that exposure to ionizing radiation has a complex 
effect on CTD tyrosine phosphorylation, depending on 
the phosphorylation site and neighboring pS and pT sta-
tus. Immunoblotting of total lysates from the HeLa cells 
used in the SILAC experiment showed a net increase in 
phospho-ATM up to 2 h after irradiation but a transient 
net increase in pY1-reactivity at 30 and 60 min after irra-
diation (Fig. 6d). The net increase in pY1 levels at 30 and 
a b
c d
Fig. 6 Effect of ionizing radiation on CTD phosphorylation. a Purification scheme used to generate partially purified RNAPII from HeLa cell nuclear 
extract. b Detection of RNAPII with three different antibodies in fractions shown in (a). c Diagram of SILAC mass spectrometry strategy used to 
examine CTD phosphorylation alterations at 0 h, 30 or 60 min relative to 2 h exposure to 8 Gy of ionizing radiation. d RNAPII and CTD phosphoryla‑
tion in IR‑treated cells. Un‑fractionated lysates from the indicated HeLa cells at the indicated time (minutes) after 8 Gy of IR were immunoblotted 
with the indicated antibodies. Note that IR stimulated the phosphorylation of ATM and increased the levels of pY1‑CTD without changing the levels 
of pS2 or pS5 CTD
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Table 5 Effect of ionizing radiation on the phosphorylation of RNA polymerase II CTD peptides
Peptide Phosphorylation site No IR IR 2 h No IR/2 h IR
YSPTSPTphosYSphosPTphosSPK [1915, 1917, 1919] 2.33E+06 4.43E+06 0.53
YSPTSPTYphosSPTphosSPK [1916, 1919] 2.79E+06 1.71E+06 1.63
YSPTphosSPTYSphosPTphosSPK [1912, 1917, 1919] 2.57E+06 3.48E+06 0.74
YSPTSphosPTYSphosPTphosSPK [1913, 1917, 1919] 3.32E+06 6.08E+06 0.55
YphosSPTSPTYphosSPTTPK [1874, 1881] 8.42E+05 9.24E+05 0.91
YphosSPTSPTYSphosPTTPK [1874, 1882] 8.08E+05 5.88E+05 1.37
YSPTSPTYSphosPTphosSPK [1917, 1919] 4.96E+06 3.16E+06 1.57
YSPTSphosPTYSPTphosSPK [1913, 1919] 4.76E+06 7.32E+06 0.65
YSPTSPTYSphosPTSphosPK [1917, 1920] 1.00E+07 6.01E+06 1.66
YSPTSphosPTYSphosPTSphosPK [1913, 1917, 1920] 3.80E+06 7.93E+06 0.48
YSPTSphosPTYSPTphosSphosPK [1913, 1919, 1920] 2.33E+06 4.43E+06 0.53
YSPTSphosPTYSphosPTSPK [1913, 1917] 2.54E+06 7.72E+05 3.29
YSPTSPTYphosSPTSphosPK [1916, 1920] 4.33E+06 2.87E+06 1.51
YphosSPTSPTYSPTSphosPK [1909, 1920] 1.40E+06 1.00E+06 1.4
YSPTSPTphosYphosSPTSPK [1915, 1916] 4.90E+06 2.85E+06 1.72
YSPTphosSPTphosYSPTphosSPK [1912, 1915, 1919] 1.42E+06 1.97E+06 0.72
YSPTSphosPTYSPTSphosPK [1913, 1920] 4.76E+06 7.32E+06 0.65
YSPTphosSPTYSphosPTSphosPK [1912, 1917, 1920] 3.50E+06 4.90E+06 0.71
YSPTSPTphosYSphosPTSphosPK [1915, 1917, 1920] 2.70E+06 5.23E+06 0.52
YphosSPTSPTYSphosPTSphosPK [1909, 1917, 1920] 3.32E+06 6.08E+06 0.55
Peptide Phosphorylation site 30 min IR 2 h IR 30 min IR/2 h IR
YphosSPTSPTYphosSPTTPK [1874, 1881] 5.91E+05 1.19E+06 0.5
YSphosPTSPTYphosSPTTPK [1875, 1881] 9.93E+05 1.49E+06 0.67
YSPTphosSPTYphosSphosPTSPK [1912, 1916, 1917] 2.22E+06 1.22E+06 1.82
YSPTphosSphosPTYSPTphosSPK [1912, 1913, 1919] 2.23E+05 1.26E+05 1.77
YphosSPTSPTYSphosPTSphosPK [1909, 1917, 1920] 2.06E+06 3.53E+06 0.58
YphosSPTSPTphosYSPTSphosPK [1909, 1915, 1920] 2.60E+06 4.02E+06 0.65
YSPTSPTYphosSPTphosSPK [1916, 1919] 5.65E+06 4.15E+06 1.36
YSPTSPTYSPTphosSphosPK [1919, 1920] 5.45E+06 4.05E+06 1.35
YSPTphosSPTYSphosPTphosSPK [1912, 1917, 1919] 2.60E+06 4.02E+06 0.65
YSPTSphosPTYSphosPTphosSPK [1913, 1917, 1919] 2.60E+06 4.02E+06 0.65
YSPTSPTYphosSphosPTSPK [1916, 1917] 5.08E+06 3.53E+06 1.44
YSPTSPTYSphosPTphosSPK [1917, 1919] 5.65E+06 4.15E+06 1.36
YSPTSphosPTYSPTphosSPK [1913, 1919] 3.14E+06 6.77E+06 0.46
YSPTSPTYSphosPTSphosPK [1917, 1920] 4.44E+06 3.47E+06 1.28
YSPTSphosPTYSphosPTSphosPK [1913, 1917, 1920] 9.64E+06 2.73E+07 0.35
YSPTSphosPTYSPTphosSphosPK [1913, 1919, 1920] 9.64E+06 2.73E+07 0.35
YSPTphosSPTYSPTphosSphosPK [1912, 1919, 1920] 1.39E+06 1.93E+06 0.72
YphosSPTSphosPTYSPTTPK [1874, 1878] 7.10E+05 1.48E+06 0.48
YSPTSPTphosYphosSPTSPK [1915, 1916] 5.08E+06 3.53E+06 1.44
YSphosPTSphosPTYSPTTPK [1875, 1878] 6.09E+05 1.30E+06 0.47
YSPTSphosPTYSPTSphosPK [1913, 1920] 4.70E+06 9.61E+06 0.49
YSphosPTSPTYSphosPTSphosPK [1910, 1917, 1920] 4.08E+06 7.53E+06 0.54
YphosSPTSPTphosYSphosPTSPK [1909, 1915, 1917] 2.24E+06 1.30E+06 1.72
YSPTphosSPTYSphosPTSphosPK [1912, 1917, 1920] 3.71E+06 1.01E+07 0.37
YSPTphosSPTYphosSphosPTTPK [1877, 1881, 1882] 1.69E+06 1.78E+06 0.95
YSPTphosSphosPTYphosSPTSPK [1912, 1913, 1916] 2.52E+06 1.19E+06 2.12
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60 min after IR treatment was likely to have resulted from 
phosphorylation at other pY1 sites that were not detected 
by the SILAC mapping of tryptic CTD peptides.
Discussions
Phosphorylation of the CTD generates “codes” for the 
selective binding of cellular proteins to regulate RNA 
processing and chromatin structure during transcrip-
tion elongation [1]. Because each of the 52 repeats of the 
CTD can be phosphorylated on multiple residues, and 
because proteins can bind to more than one repeat, the 
theoretical complexity of the “CTD code” is immense. 
In this study, we show that synthetic peptides with four 
heptad repeats of CTD can be used to pull-down mam-
malian cellular proteins that directly or indirectly inter-
act with the CTD. This approach has identified proteins 
containing the well-established CTD-interacting domain 
(CID). This approach also led to the finding that CTD-
tyrosine phosphorylation could interfere with the direct 
binding of CID to pS2-CTD consistent with a recently 
published report that CTD-tyrosine phosphorylation 
inhibits RNAPII interaction with the Pcf11 transcription 
termination factor [17]. However, the mass spectrometry 
analysis has also identified several proteins that inter-
acted with tyrosine/serine doubly phosphorylated CTD 
peptides.
Conclusions
While the CTD peptide-pull down method cannot dis-
tinguish between direct or indirect binding to alterna-
tively phosphorylated CTD-repeats, it provides a way to 
survey the proteomic landscape associated with specified 
Table 5 continued
Peptide Phosphorylation site 1 h IR 2 h IR 1 h IR/2 h IR
YphosSPTSphosPTYSPT‑
SphosPK
[1909, 1913, 1920] 4.69E+06 1.98E+06 2.37
YphosSPTSPTphosYSPT‑
SphosPK
[1909, 1915, 1920] 2.59E+06 3.55E+06 0.73
YSPTSPTYphosSPTphosSPK [1916, 1919] 5.08E+06 3.58E+06 1.42
YSPTSphosPTYSphosPT‑
phosSPK
[1913, 1917, 1919] 1.81E+06 2.72E+06 0.67
YphosSPTSPTYphosSPTTPK [1874, 1881] 6.79E+05 9.01E+05 0.75
YSphosPTSPTYphosSPTTPK [1875, 1881] 7.12E+05 1.10E+06 0.65
YSPTSPTYSphosPTphosSPK [1917, 1919] 6.85E+06 4.61E+06 1.49
YSPTSphosPTYSPTphosSPK [1913, 1919] 3.20E+06 4.32E+06 0.74
YSPTSPTYSphosPTSphosPK [1917, 1920] 6.85E+06 4.61E+06 1.49
YSPTSphosPTYSphosPT‑
SphosPK
[1913, 1917, 1920] 9.32E+06 2.01E+07 0.46
YSPTSphosPTYSPTphosS‑
phosPK
[1913, 1919, 1920] 3.70E+06 7.89E+06 0.47
YphosSPTSPTYSPTSphosPK [1909, 1920] 3.78E+06 5.11E+06 0.74
YSPTSphosPTYphosSPTTPK [1878, 1881] 5.57E+05 2.99E+05 1.86
YSPTphosSPTYphosSPTTPK [1877, 1881] 7.12E+05 1.10E+06 0.65
YSPTSPTphosYphosSPTSPK [1915, 1916] 1.27E+06 7.11E+05 1.79
YSPTSphosPTYSPTSphosPK [1913, 1920] 3.78E+06 5.11E+06 0.74
YSphosPTSPTYSphosPT‑
SphosPK
[1910, 1917, 1920] 1.58E+06 3.75E+06 0.42
YSPTphosSphosPTY‑
phosSPTSPK
[1912, 1913, 1916] 1.30E+06 7.23E+05 1.8
YSPTphosSPTYSphosPT‑
SphosPK
[1912, 1917, 1920] 4.90E+06 1.06E+07 0.46
YSPTphosSPTphosYSPT‑
SphosPK
[1912, 1915, 1920] 4.56E+06 6.41E+06 0.71
YSPTSPTphosYSphosPT‑
SphosPK
[1915, 1917, 1920] 1.61E+06 2.42E+06 0.67
Lists CTD phospho-peptides identified in the SILAC MS analyses of partially purified RNA polymerase II from HeLa cells exposed to ionizing radiation (IR, 8 Gy) for the 
indicated time. The peptide column lists phosphopeptides identified. Amino acid to the left of “phos” is phosphorylated. The phosphorylation sites in each peptide 
are listed in the second column. The signals and the ratio from light and heavy peptides are listed in the remaining columns. A ratio >1 represents a reduction in that 
phospho-peptide at 2 h relative to 0 h, 30 min or 1 h after IR. A ratio <1 represents an increase in that phospho-peptide at 2 h relative to 0 h, 30 min or 1 h after IR
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combinations of CTD repeat sequences and phosphoryl-
ation. This method can also be used to identify proteins 
that associate with regions of the CTD that contain non-
consensus heptad repeats.
Availability of supporting data
All supporting data have been deposited to the MassIVE 
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CTD: C‑terminal repeated domain; RNAPII: RNA polymerase II; CID: CTD‑inter‑
acting domain; MUDPIT: multidimensional protein identification technology 
(MUDPIT) mass spectrometry.
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